Literature DB >> 23763460

Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012.

Michel Meignan1, Sally Barrington, Emmanuel Itti, Andrea Gallamini, Corinne Haioun, Aaron Polliack.   

Abstract

One hundred and seventy-five hemato-oncologists and nuclear medicine specialists from 23 countries joined the 2-day 4th International Workshop on Positron Emission Tomography in Lymphoma held in October 2012. The meeting was under the auspices of the European Lymphoma Institute, the Lymphoma Study Association (LYSA) and Fondazione Italiana Linfomi (FIL). Thirty-nine scientific posters were presented or discussed in the plenary session. A group of nuclear medicine and radiology experts presented and discussed with the audience their final report on lymphoma staging and restaging with positron emission tomography (PET). The same report will be presented in a dedicated workshop during the 12th International Conference on Malignant Lymphoma (ICML) in Lugano. Mainly, it was proposed to use the same type of criteria (Deauville five-point scale) for interim and end of treatment PET reporting. Results were presented on the state of the art of the role of PET in staging and response assessment in follicular lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma and T cell lymphoma. Although PET is now recognized as a useful tool in follicular lymphoma, prospective data should be acquired on a larger scale to better define its role in the other subtypes. Technical and clinical focus was given to the measurement of metabolic volume to evaluate the total tumor burden, and interim PET-based ongoing trials were presented for LYSA and FIL. Final results of international validation studies of Deauville criteria and change in maximum standardized uptake value (ΔSUVmax) analysis were presented for Hodgkin lymphoma and diffuse large B-cell lymphoma. A closed meeting was held addressing the issue of contrast-enhanced computed tomography (CT) in the PET/CT era. The next meeting (September 2014) will be open to all imaging modalities used for lymphoma investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23763460     DOI: 10.3109/10428194.2013.802784

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  29 in total

1.  Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.

Authors:  Heiko Schöder; Andrew D Zelenetz; Paul Hamlin; Somali Gavane; Steven Horwitz; Matthew Matasar; Alison Moskowitz; Ariela Noy; Lia Palomba; Carol Portlock; David Straus; Ravinder Grewal; Jocelyn C Migliacci; Steven M Larson; Craig H Moskowitz
Journal:  J Nucl Med       Date:  2015-12-30       Impact factor: 10.057

2.  Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.

Authors:  Massimo Federico; Stefano Luminari; Cinzia Pellegrini; Francesco Merli; Emanuela Anna Pesce; Stephane Chauvie; Letizia Gandolfi; Isabella Capodanno; Massimiliano Salati; Lisa Argnani; Pier Luigi Zinzani
Journal:  Haematologica       Date:  2015-12-24       Impact factor: 9.941

Review 3.  Impact of (18)F-FDG PET/CT on the staging and management of follicular lymphoma.

Authors:  U Metser; D Hussey; G Murphy
Journal:  Br J Radiol       Date:  2014-07-25       Impact factor: 3.039

4.  A prospective study of mediastinal gray-zone lymphoma.

Authors:  Wyndham H Wilson; Stefania Pittaluga; Alina Nicolae; Kevin Camphausen; Margaret Shovlin; Seth M Steinberg; Mark Roschewski; Louis M Staudt; Elaine S Jaffe; Kieron Dunleavy
Journal:  Blood       Date:  2014-07-14       Impact factor: 22.113

5.  Do myocardial PET-MR and PET-CT FDG images provide comparable information?

Authors:  Jorge D Oldan; Shetal N Shah; Richard C Brunken; Frank P DiFilippo; Nancy A Obuchowski; Michael A Bolen
Journal:  J Nucl Cardiol       Date:  2015-06-13       Impact factor: 5.952

6.  Deauville score: the Phoenix rising from ashes.

Authors:  Egesta Lopci; Michel Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-14       Impact factor: 9.236

7.  Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan.

Authors:  Dirk Hasenclever; Lars Kurch; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11       Impact factor: 9.236

8.  The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria.

Authors:  Elske Quak; Narinée Hovhannisyan; Charline Lasnon; Christophe Fruchart; Jean-Pierre Vilque; Dada Musafiri; Nicolas Aide
Journal:  Haematologica       Date:  2014-02-28       Impact factor: 9.941

Review 9.  RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Authors:  Lawrence H Schwartz; Lesley Seymour; Saskia Litière; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Elisabeth de Vries
Journal:  Eur J Cancer       Date:  2016-05-26       Impact factor: 9.162

10.  qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.

Authors:  Dirk Hasenclever; Lars Kurch; Christine Mauz-Körholz; Andreas Elsner; Thomas Georgi; Hamish Wallace; Judith Landman-Parker; Angelina Moryl-Bujakowska; Michaela Cepelová; Jonas Karlén; Ana Álvarez Fernández-Teijeiro; Andishe Attarbaschi; Alexander Fosså; Jane Pears; Andrea Hraskova; Eva Bergsträsser; Auke Beishuizen; Anne Uyttebroeck; Eckhard Schomerus; Osama Sabri; Dieter Körholz; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-07       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.